185 related articles for article (PubMed ID: 38302159)
1. Phase II Trial Assessing the Repeatability and Tumor Uptake of [
Gondry O; Caveliers V; Xavier C; Raes L; Vanhoeij M; Verfaillie G; Fontaine C; Glorieus K; De Grève J; Joris S; Luyten I; Zwaenepoel K; Vandenbroucke F; Waelput W; Thyparambil S; Vaneycken I; Cousaert J; Bourgeois S; Devoogdt N; Goethals L; Everaert H; De Geeter F; Lahoutte T; Keyaerts M
J Nucl Med; 2024 Feb; 65(2):178-184. PubMed ID: 38302159
[TBL] [Abstract][Full Text] [Related]
2. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
[TBL] [Abstract][Full Text] [Related]
3. Human Epidermal Growth Factor Receptor 2-Targeting [
Alhuseinalkhudhur A; Lindman H; Liss P; Sundin T; Frejd FY; Hartman J; Iyer V; Feldwisch J; Lubberink M; Rönnlund C; Tolmachev V; Velikyan I; Sörensen J
J Nucl Med; 2023 Sep; 64(9):1364-1370. PubMed ID: 37442602
[TBL] [Abstract][Full Text] [Related]
4. Clinical Translation of [
Xavier C; Blykers A; Laoui D; Bolli E; Vaneyken I; Bridoux J; Baudhuin H; Raes G; Everaert H; Movahedi K; Van Ginderachter JA; Devoogdt N; Caveliers V; Lahoutte T; Keyaerts M
Mol Imaging Biol; 2019 Oct; 21(5):898-906. PubMed ID: 30671739
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Phase I Study of [
Gondry O; Xavier C; Raes L; Heemskerk J; Devoogdt N; Everaert H; Breckpot K; Lecocq Q; Decoster L; Fontaine C; Schallier D; Aspeslagh S; Vaneycken I; Raes G; Van Ginderachter JA; Lahoutte T; Caveliers V; Keyaerts M
J Nucl Med; 2023 Sep; 64(9):1378-1384. PubMed ID: 37474271
[TBL] [Abstract][Full Text] [Related]
7. Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [
Altena R; Burén SA; Blomgren A; Karlsson E; Tzortzakakis A; Brun N; Moein MM; Jussing E; Frejd FY; Bergh J; Tran TA; Hartman J; Axelsson R
J Nucl Med; 2024 May; 65(5):700-707. PubMed ID: 38548353
[TBL] [Abstract][Full Text] [Related]
8. Impact of
Zhou N; Liu C; Guo X; Xu Y; Gong J; Qi C; Zhang X; Yang M; Zhu H; Shen L; Yang Z
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):161-175. PubMed ID: 32564171
[TBL] [Abstract][Full Text] [Related]
9. PET imaging of a
Xu Y; Wang L; Pan D; Yu C; Mi B; Huang Q; Sheng J; Yan J; Wang X; Yang R; Yang M
Br J Radiol; 2019 Dec; 92(1104):20190425. PubMed ID: 31593482
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of
Nguyen A; Fullard K; Sheehan-Dare G; Tang R; Chan L; Ho B; Dear R; Keane J; Hickey A; Nandurkar R; Chen J; Chen A; Lim E; Emmett L
J Med Imaging Radiat Oncol; 2022 Sep; 66(6):731-737. PubMed ID: 34676675
[TBL] [Abstract][Full Text] [Related]
11. A prospective head-to-head comparison of
Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhu Z
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4218-4227. PubMed ID: 35657429
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
[TBL] [Abstract][Full Text] [Related]
13. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with
Risør LM; Clausen MM; Ujmajuridze Z; Farhadi M; Andersen KF; Loft A; Friborg J; Kjaer A
J Nucl Med; 2022 Aug; 63(8):1169-1176. PubMed ID: 34857658
[TBL] [Abstract][Full Text] [Related]
15. Imaging CXCR4 receptors expression for staging multiple myeloma by using
Shekhawat AS; Singh B; Malhotra P; Watts A; Basher R; Kaur H; Hooda M; Radotra BD
Br J Radiol; 2022 Aug; 95(1136):20211272. PubMed ID: 35731811
[TBL] [Abstract][Full Text] [Related]
16. Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.
Sörensen J; Velikyan I; Sandberg D; Wennborg A; Feldwisch J; Tolmachev V; Orlova A; Sandström M; Lubberink M; Olofsson H; Carlsson J; Lindman H
Theranostics; 2016; 6(2):262-71. PubMed ID: 26877784
[TBL] [Abstract][Full Text] [Related]
17. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.
Mortimer JE; Bading JR; Colcher DM; Conti PS; Frankel PH; Carroll MI; Tong S; Poku E; Miles JK; Shively JE; Raubitschek AA
J Nucl Med; 2014 Jan; 55(1):23-9. PubMed ID: 24337604
[TBL] [Abstract][Full Text] [Related]
18. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B
BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367
[TBL] [Abstract][Full Text] [Related]
19.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
20. Detection of HER2 expression using
Zhao L; Xing Y; Liu C; Ma S; Huang W; Cheng Z; Zhao J
Breast Cancer Res; 2024 Mar; 26(1):40. PubMed ID: 38459598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
